News

Amgen’s leukaemia immunotherapy Blincyto has demonstrated complete remission in a phase II trial testing the drug in a new indication.

Almirall took centre stage at the PharmaTimes Sales & MSL Awards 2015 on July 9, taking home the prize for Sales Company of the Year, along with Key Account Manager of the Year, which was won by Faruk Dasu.

AstraZeneca has hooked up with Vida Health to launch a new smartphone app designed to speed up the recovery of patients who have suffered a heart attack. 

The British Medical Association and the Health Secretary seem at loggerheads over the logistics of a seven-day National Health Service, with Jeremy Hunt telling the doctor’s union he will impose a new contract if negotiations to support the plans are unsuccessful.

Organiser PharmaTimes Media invites healthcare communications agencies to seize the opportunity to develop their skills and abilities.

European regulators have approved Bristol-Myers Squibb’s Evotaz pills in combination with other antiretroviral agents for the treatment of adult patients infected with HIV-1.

UK biotech Immuncore will be celebrating the success of a private financing round that has added some $320 million (£205 million) to its books, breaking the European record.

Adam Chapman, Senior Brand Manager at Lundbeck winner of Brand Manager of the Year 2014 at the PharmaTimes Marketer of the Year awards, explains the value of entering the PharmaTimes Marketer of the Year competition:

Sanofi has unveiled plans to carve up its operations into five global business units in the hope of maximising growth opportunities and optimising innovation and new drug development.

Another day, another pharma-academia hook-up, and this time its Bristol-Myers Squibb and the Medical University of South Carolina combining forces to study fibrotic diseases.

Celgene is laying more than $7 billion on the table to buy San Diego-based biotech Receptos, in a move that will significantly boost its inflammation and immunology portfolio.

GlaxoSmithKline, the Medical Research Council and UK academia are working together on a unique open innovation research initiative which strives to improve understanding of inflammatory diseases in the hope of paving the way for new treatments.

A Phase II clinical study* of an Ebola vaccine regimen being developed by Janssen and Bavarian Nordic has kicked off with healthy volunteers in England and France.

Oxford Health NHS Foundation Trust is being investigated by Monitor because of persistent cash problems, in what seems to be yet another example of the deteriorating state of trust finances across the country.   

Takeda has submitted an application in the US to market its experimental cancer drug ixazomib for the treatment of patients with relapsed and/or refractory multiple myeloma.